Related Experiment Videos
[A clinical study of PC-904 in pediatrics (author's transl)]
Insights
This study evaluated PC-904 in children for bacterial infections. PC-904 demonstrated a 71.4% efficacy rate with no observed side effects, suggesting its potential as a safe and effective treatment.
Area of Science:
- Pediatric infectious diseases
- Pharmacokinetics and pharmacodynamics
- Antibacterial agents
Background:
- PC-904 is an antibacterial agent investigated for pediatric use.
- Bacterial infections in children necessitate effective and safe therapeutic options.
Observation:
- Serum levels of PC-904 were analyzed following single intravenous administration.
- Clinical efficacy and bacteriological response were assessed in pediatric patients with various infections.
- Patient populations included those with acute pharyngitis, bronchitis, pneumonia, lymphadenitis, abscesses, and urinary tract infections.
Findings:
- A recommended dosage of 50-100 mg/kg/day in 3-4 divided intravenous doses was suggested based on pharmacokinetic data.
- PC-904 showed a 71.4% efficacy rate in treating pediatric bacterial infections.
- Bacteriological eradication or reduction was observed in 8 out of 11 cases.
- No adverse side effects or laboratory abnormalities were reported during the study.
Implications:
- PC-904 shows promise as a safe and effective treatment for pediatric bacterial infections.
- Further clinical trials may be warranted to confirm these findings and establish optimal dosing regimens.
- The favorable safety profile of PC-904 could make it a valuable addition to the pediatric infectious disease pharmacopeia.
Abstract:
A clinical study of PC-904 was performed in children. The results were as follows; 1) Serum levels of PC-904 after single administration of 20 mg/kg were studied in patients by one-shot intravenous injection or drip infusion for 1 hour or 2 hours. The results obtained in this fundamental study led to the suggestion that the proper dosage in bacterial infections would be 50 approximately 100 mg/kg intravenously in 3 approximately 4 divided doses daily. 2) A clinical study of PC-904 was performed in 16 patients including acute pharyngitis and bronchitis (3 cases), acute bronchopneumonia (3 cases), pertussis pneumonia (1 case), lymphadenitis purulenta (2 cases), acute bronchopneumonia (3 cases), pertussis pneumonia (1 case), lymphadenitis purulenta (2 cases), abscess with chronic granuloma (2 cases) and urinary tract infection (5 cases). About 50 approximately 100 mg/kg of PC-904 were administered in 3 approximately 4 divided doses daily by one-shot intravenous injection. The clinical effects of 2 cases out of 16 were impossible to be evaluated, and thses cases were excluded from the clinical evaluation. Ten cases out of 14 showed excellent or good responses (efficacy rate: 71.4%). 3) The bacteriological examinations were performed and the causative or isolated organisms were determined in 11 cases. The responses were "disappeared" in 6 cases, "decreased" in 2 cases and "not disappeared" in 3 cases. 4) No side effects were observed. Abnormalities of laboratory findings were not also noticed.